Comments
Pharma major Dr Reddy’s Laboratories Ltd has launched Carboprost Tromethamine Injection, a therapeutic equivalent generic version of Hemabate injection approved by the US Food and Drug Administration (USFDA).
“We are pleased to be first-to-market with this product that has been designated as a Competitive Generic Therapy (CGT) by the FDA,” Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories said in a release issued here on Wednesday. “With a CGT designation, we have 180-day CGT exclusivity to market this product,’’ he added.
The Hemabate injection brand had US sales of approximately $55 million for the most recent twelve months ending in April 2019 according to IQVIA Health. Hemabate is a trademark of Pfizer.
At 2.40 pm, the stocks of Dr Reddy’s were trading 1.07 per cent lower at ₹2,600.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.